Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.

The pharmacogenomics journal - 29 Jun 2026

Rodríguez-Piñas J M, Romero-Lorca A, Novillo A, Gaibar M, Rubio M, Antón-Pascual B, Hernando S, Alemany I, Camacho F I, Cavanagh M, Boiza M, Marrupe D, Martín A M, Khedaoui R, Fernández-Santander A

Abstract excerpt

The treatment of urothelial cancer (UC) has been revolutionized by the introduction of immune checkpoint inhibitors (ICIs). However, while ICIs have achieved better therapeutic results than traditional chemotherapeutic agents, immune-related adverse events (irAEs) can lead to poor treatment outcomes. This exploratory study was designed to seek tumour single-nucleotide polymorphisms (SNPs) related to irAEs in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Polymorphism, Single Nucleotide

Share to Risk Factors

Share to Urologic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42373597
DOI: 10.1038/s41397-026-00423-3
PMCID: PMC13314534

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.PMID 42373597Read ↗

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variantsSemantic proximity Read ↗

Polygenic Risk for Skin Autoimmunity Impacts Immune Checkpoint Blockade in Bladder CancerSemantic proximity Read ↗

Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.Semantic proximity Read ↗

Single-Nucleotide Polymorphisms (SNPs) Can Predict the Efficacy and Toxicity of Cancer Immunotherapy? A Systematic ReviewSemantic proximity Read ↗

The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response.Semantic proximity Read ↗

Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.Semantic proximity Read ↗

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicitySemantic proximity Read ↗

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitisSemantic proximity Read ↗

PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohortSemantic proximity Read ↗

Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.Semantic proximity Read ↗

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.Semantic proximity Read ↗

Association Between Genetic Variants and the Risk of Nivolumab-Induced Immune-Related Adverse EventsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.